Immutep Reports New Data In Head And Neck Cancer At ESMO Immuno-Oncology 2024; Complete Response Rate Increases To 12.9% And 16.1%, According To RECIST 1.1 And IRECIST, Respectively; Treatment Continues To Be Well Tolerated

Benzinga · Dec 12 21:24

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1
Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls
Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively
Treatment continues to be well tolerated

SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with negative PD-L1 expression.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Immutep Reports New Data In Head And Neck Cancer At ESMO Immuno-Oncology 2024; Complete Response Rate Increases To 12.9% And 16.1%, According To RECIST 1.1 And IRECIST, Respectively; Treatment Continues To Be Well Tolerated

Risk Disclaimer